HCV Treatment at The Liver Meeting: Selected Highlights

The Liver Meeting, organised by the American Association for the Study of Liver Diseases (AASLD), was held as a hybrid event from 4 to 8 November 2022.

Here are selected highlights from The Liver Meeting in relation to the HCV treatment:

• Increasing time since eradication of HCV is independently associated with a lower risk of HCC
• Glecaprevir/pibrentasvir (G/P) and ezetimibe for 8 days should be the new standard of care with 100% efficacy to prevent chronic HCV infection in non-liver solid organ transplant recipients of HCV-VIREMIC grafts
• Patients with chronic hepatitis C could be treated with sofosbuvir/velpatasvir for 12 weeks by non-specialists: 2nd interim analysis of prospective study Helios-3
• Ultra-short course glecaprevir/pibrentasvir with ezetimibe in the prevention of hepatitis c (HCV) transmission from HCV-positive organ donors to HCV-negative recipients: ongoing experience
• Hepatitis C virus prevalence and outcomes among pregnant women who inject drugs
• High HCV SVR in rural US group with heavy use of opioids, other drugs
• Curing HCV with DAA treatment: Adherence and rapid onset of HCV-RNA undetectability after 4 weeks of treatment with sofosbuvir/velpatasvir
• Effectiveness of voxilaprevir/velpatasvir/sofosbuvir in hepatitis C patients previously treated with DAAs